Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
NCT00723125
Completed
In the MDACC/BrUOG neoadjuvant trial with weekly paclitaxel followed by Fluorouracil Plus Doxorubicin and Cyclophosphamide (FAC), the pathologic complete response (pCR) rate in HER2(-) patients was 20%. The investigators' goal is to develop an induction chemotherapy regimen that will have a pCR rate above 30% in patients with HER2(-) disease. Based on a 1-sided 95% confidence interval using normal approximation with an expected pCR rate of at least 35%, approximately 28 patients are required for... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/06/2021
Locations: Bridgeport Hospital, Bridgeport, Connecticut +4 locations
Conditions: Breast Cancer
Register for Updates
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
NCT02155088
Completed
The main purpose of this study is to see primarily if BYL719 is safe to be given to patients in combination with gemcitabine and nab-paclitaxel. Gemcitabine and nab-paclitaxel is an FDA-approved regimen to treat pancreatic cancer. Secondary goals will be to find out the effect on tumor of this new drug combination of BYL719, gemcitabine and nab-paclitaxel. In the first part of the study, different doses of BYL719 will be tested. In the second part of the study, all patients will be started at th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
NCT02468557
Terminated
The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2021
Locations: Scottsdale Healthcare Clinical Research Institute, Scottsdale, Arizona +8 locations
Conditions: Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Register for Updates
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
NCT02041429
Completed
This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer. Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that may be important in cancer, including breast cancer. Blocking this pathway may stop cancer cells from growing. Ruxolitinib has been approved by the FDA for patients with bone marrow disease, and this is the first study using... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2021
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Recurrent Breast Cancer, Metastatic Breast Cancer
Register for Updates
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
NCT03563170
Withdrawn
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2021
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Register for Updates
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
NCT00945191
Completed
This trial assessed the effect of treatment with CS-1008 in combination with paclitaxel/carboplatin on response in patients with locally advanced or metastatic ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2021
Locations: Univ. Alabama, Birmingham, Alabama +2 locations
Conditions: Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Register for Updates
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
NCT02501902
Completed
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2021
Locations: Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona +25 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma
NCT01839799
Completed
Determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2021
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreatic Adenocarcinoma
Register for Updates
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
NCT01716195
Completed
The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2021
Locations: University of California Comprehensive Cancer Center, Sacramento, California
Conditions: Head and Neck Cancer
Register for Updates
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
NCT01820754
Completed
The purpose of this study is to evaluate whether the combination of neoadjuvant chemotherapy (chemotherapy before surgery) plus ipilimumab for lung cancer increases the number of patients with detectable circulating T cells with specificities against tumor associated antigens (TAA) from zero percent (0%) of patients prior to therapy to 20% of patients after neoadjuvant chemotherapy plus ipilimumab. This is an open label Phase 2 trial. Patients with clinical stage 1B (\>4 cm), 2, (N0-2) or 3 non... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2021
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
NCT02162719
Completed
This multicenter, randomized, double-blind study will estimate the efficacy, safety and tolerability of ipatasertib combined with paclitaxel compared with placebo combined with paclitaxel in participants with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC), as measured by progression-free survival (PFS) in all participants and in participants with phosphatase and tensin homolog (PTEN)-low tumors.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2021
Locations: St Jude Heritage Medical Group, Fullerton, California +43 locations
Conditions: Breast Neoplasms
Register for Updates
Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer
NCT00397761
Withdrawn
RATIONALE: Drugs used in chemotherapy, such as capecitabine and paclitaxel (albumin-stablized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II/III trial is studying how well giving capecitabine together with paclitaxel... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
02/15/2021
Locations: Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia
Conditions: Breast Cancer
Register for Updates